Honorees

 

 

This year’s gala will recognize two outstanding individuals whose work has significantly contributed to improving the quality of life of anyone who is touched by cancer. Richard T. Clark, Chairman, President and CEO of Merck & Co., Inc. will accept the Corporate Vision Award and Dr. David Scheinberg, Chairman of the Molecular Pharmacology and Chemistry Program in Sloan-Kettering Institute will accept the Advancement of Cancer Research Award.

 

 


Richard T. Clark

 

Corporate Vision Award

 

Richard T. Clark is the Chairman, President and Chief Executive Officer of Merck & Co., Inc., a global research-driven pharmaceutical company that discovers, develops, manufactures and markets innovative medicines and vaccines. Mr. Clark has been President and CEO of Merck since May 2005, and chairman of the board since April 2007.

Previously Mr. Clark held the position of President of the Merck Manufacturing Division, with responsibility for Merck’s global network of manufacturing operations, information services and operational excellence organizations worldwide.

In a career spanning more than 36 years with Merck, Mr. Clark has held a broad range of senior management positions within the company’s manufacturing organization. Mr. Clark joined Merck in 1972 as a Quality Control Inspector, and he progressed through a series of increasingly responsible roles in the areas of production, new products planning, industrial engineering and management engineering, becoming Vice President, Materials Management and Management Engineering in 1991.

     

In 1993, Mr. Clark was appointed Vice President, Procurement and Materials Management. He became Vice President of North American Operations for the Merck Manufacturing Division in 1994 and Senior Vice President in 1996. In 1997, he was appointed Senior Vice President of Quality and Commercial Affairs. Later that year, Mr. Clark joined the Merck-Medco Managed Care subsidiary as Executive Vice President and Chief Operating Officer. He later served as Chairman, President and Chief Executive Officer of the newly named Medco Health Solutions, overseeing plans to prepare that organization to become a publicly traded company. He returned to the Merck Manufacturing Division as President in June 2003.

From 2008 to 2009 he served as board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country's leading pharmaceutical research and biotechnology companies. Mr. Clark earned his bachelor’s degree in Liberal Arts from Washington & Jefferson College, and his M.B.A. from American University. He served as a Lieutenant in the U.S. Army from 1970 to 1972 before joining Merck.
    

 

___________________________________________________________________________

 

 

 

David A. Scheinberg

 

Advancement of Cancer Research Award

 

David A. Scheinberg, M.D., Ph.D. is currently Vincent Astor Chair and Chairman, Molecular Pharmacology and Chemistry Program. He also founded and Chairs the Experimental Therapeutics Center, Memorial Sloan-Kettering Cancer Center. He is additionally Professor of Medicine and Pharmacology and Co-chair of the Pharmacology graduate program at the Weill-Cornell University Medical College and Professor in the Gerstner Sloan-Kettering Graduate School at MSKCC. From 1992 until 2003, he was Chief of the Leukemia Service at Memorial Hospital.

 

Dr. Scheinberg is a physician-scientist, specializing in the care of patients with leukemia. His research centers around the discovery of, development of, and principles of use for, novel, specific, immunotherapeutic agents for the treatment of leukemia and other cancers. Eight different therapeutic agents (cancer vaccines, antibodies, targeted radiopharmaceuticals and targeted alpha emitters), developed by Dr. Scheinberg in his laboratory have reached human clinical trials. Dr. Scheinberg has published more than 200 papers, chapters, or books in these fields.

     

His awards include the Doris Duke Distinguished Clinical Science Professorship, the Lucille P. Markey Scholarship, Leukemia and Lymphoma Society Translational Investigator Awards, CapCure Awards, and election into the American Society of Clinical Investigation, the American Association of Physicians, and the Interurban Club. He Co-Chairs the Medical Board of the Laurie Strauss Leukemia Foundation, is a Director of Progenics Pharmaceuticals, a public biotech company, and he sits on the advisory boards of cancer centers and charitable foundations.